Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
| Market Cap | 10.11B+0.5% |
| Revenue (ttm) | 1.28B+149.0% |
| Net Income | -325.10M-15.3% |
| EPS | -12.89-0.3% |
| Shares Out | 23.10M |
| PE Ratio | n/a |
| Forward PE | 77.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 275,780 |
| Open | 435.27 |
| Previous Close | 434.24 |
| Day's Range | 435.27 - 442.98 |
| 52-Week Range | 393.61 - 615.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 686.44(+56.81%) |
| Earnings Date | Nov 3, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Nov 3, 2026Earnings report
Ask Barron about MDGL
$MDGL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MDGL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MDGL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MDGL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MDGL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MDGL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MDGL
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $296.22M |
| VBVanguard Morningstar Small-Cap ETF | $209.72M |
| XBIState Street SPDR S&P Biotech ETF | $126.83M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $116.77M |
| VXFVanguard Extended Market ETF | $112.83M |
| FBTFirst Trust NYSE Arca Biotechnology Index Fund | $90.13M |
Estimated from each fund’s disclosed top holdings × AUM
MDGL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MDGL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score